Filtered By:
Procedure: Hemodialysis
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 19521 results found since Jan 2013.
Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease
CONCLUSIONS: Tenapanor is the first drug in its class that lowers hyperphosphatemia in ESKD patients through a novel mechanism of action involving paracellular inactive transport. Although more studies are needed, early results indicate that tenapanor may have a place in managing hyperphosphatemia in ESKD patients both as monotherapy and as an adjunct to existing phosphate binder therapy.PMID:35041802 | DOI:10.18433/jpps32284
Source: J Pharm Pharm Sci - January 18, 2022 Category: Drugs & Pharmacology Authors: Tiffany Lin Akram Al-Makki Brian Shepler Source Type: research
